Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582579 | 1.00 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL26553755 | 1.00 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL1582583 | 1.00 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL29138069 | 0.93 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL26553775 | 0.93 | TAS1R3 (0.54) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL26298181 | 0.93 | TAS1R3 (0.54) | KDM4ETAS1R3TAS1R1HPGDMEN1 | |
| SCHEMBL23679990 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 | |
| SCHEMBL21878146 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 | |
| SCHEMBL22883375 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 | |
| SCHEMBL23425430 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9885082-B2 | Embodiments of a probe and method for targeting nucleic acids | UNIVERSITY OF IDAHO (US) | 2018-02-06 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | KDM4E 3824/4885TAS1R3 4231/4885TAS1R1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.